Sudeep Pharma IPO opens for subscription from November 21, 2025, to November 25, 2025, with listing expected on BSE and NSE on November 28, 2025. The IPO issue size is ₹895 crore, including a fresh issue of ₹95 crore and an offer for sale of ₹800 crore. Sudeep Pharma is a prominent manufacturer of pharmaceutical excipients and specialty ingredients, catering to global clients in the pharma, food, and nutraceutical sectors. Sudeep Pharma IPO offers investors exposure to a growing sector marked by rising demand for specialty ingredients, robust export presence, and operational expansion strategies.
₹105
₹593
₹730.00
Expert Opinions
Market sentiment for Sudeep Pharma IPO is favorable, supported by consistent financial growth and a strong position in pharmaceutical excipients and specialty ingredients. The company’s strengths include established global client relationships, robust export presence, and leadership in its niche segment. Risks involve customer concentration, regulatory compliance, and raw material price volatility.
Valuation analysis of Sudeep Pharma IPO and year 2025 highlights a Return on Equity (ROE) of 28.13%, ROCE of 29.82%, and Net Asset Value (NAV) of ₹45.86, reflecting efficient use of assets and substantial profitability. From a long-term perspective, the IPO suits investors seeking to tap into rising demand for pharma ingredients and sustained export growth, with prospects reinforced by capital expenditure and production upgrades planned by Sudeep Pharma.
Investor Considerations
Sudeep Pharma IPO investors should note the company’s robust performance, with revenue and profit after tax growing consistently, reflected in FY 2025 financials. The sector outlook remains favorable, driven by rising global demand for pharmaceutical excipients and specialty ingredients. Valuation analysis for Sudeep Pharma IPO in 2025 shows a Price to Book Value of 12.93, PAT Margin of 27.63%, and a low Debt/Equity ratio of 0.20, indicating strong profitability and conservative financial leverage.
Growth prospects are supported by operational expansions, R&D focus, and a broadening export footprint. Risks include customer concentration, segment dependency, and regulatory challenges. The IPO aligns well with long-term investors targeting stable growth and sector tailwinds, while short-term investors should consider market valuations and associated volatility.
| Date | GMP | Trend |
|---|---|---|
| 27 Nov 2025 20.11 | ₹105 | Up |
| 24 Nov 2025 20.19 | ₹80 | Down |
| 22 Nov 2025 19.01 | ₹115 | --- |
| 20 Nov 2025 20.13 | ₹115 | Down |
| 19 Nov 2025 19.37 | ₹120 | --- |
FAQs
The Grey Market Premium showed good accuracy in predicting Sudeep Pharma IPO’s listing performance. With a final GMP of ₹105, it projected a premium of about 17.7% over the issue price of ₹593, while the stock actually listed at ₹730 in the pre-open market, delivering a stronger gain of around 23%. This resulted in a moderate prediction error of roughly 5.3%, meaning the GMP correctly signaled a positive listing but slightly underestimated the actual gain, reflecting strong reliability in this case.
Sudeep Pharma IPO Current GMP is ₹105.
Sudeep Pharma IPO Expected Returns is 17.71%.
Sudeep Pharma IPO estimated listing price is ₹698.